Point72 Asset Management
URGN icon

Point72 Asset Management’s UroGen Pharma URGN Stock Holding History

Point72 Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-168,779
Closed -$2.31M – 2702
2025
Q2 		$2.31M Sell
168,779
-67,227
-28% -$645K ﹤0.01% 1241
2025
Q1 		$2.61M Sell
236,006
-81,108
-26% -$865K 0.01% 1159
2024
Q4 		$3.38M Sell
317,114
-1,189,532
-79% -$14.2M 0.01% 1069
2024
Q3 		$19.1M Sell
1,506,646
-942,631
-38% -$14M 0.05% 432
2024
Q2 		$41.1M Buy
2,449,277
+1,337,257
+120% +$19M 0.11% 248
2024
Q1 		$16.7M Buy
1,112,020
+986,020
+783% +$16.1M 0.04% 521
2023
Q4 		$1.89M Sell
126,000
-81,733
-39% -$1.06M ﹤0.01% 1229
2023
Q3 		$2.91M Buy
+207,733
New +$3.33M 0.01% 1040
2020
Q1 		– Sell
-222,024
Closed -$7.41M – 1095
2019
Q4 		$7.41M Buy
222,024
+164,222
+284% +$4.48M 0.04% 436
2019
Q3 		$1.38M Buy
57,802
+290
+0.5% +$9.48K 0.01% 644
2019
Q2 		$2.07M Sell
57,512
-206,087
-78% -$7.6M 0.01% 647
2019
Q1 		$9.74M Buy
263,599
+198,599
+306% +$8.33M 0.04% 412
2018
Q4 		$2.8M Buy
65,000
+12,954
+25% +$582K 0.01% 668
2018
Q3 		$2.46M Buy
+52,046
New +$2.42M 0.01% 733

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Point72 Asset Management's URGN Position: Q3 2025 in Review

Point72 Asset Management sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 168,779 shares — an estimated $2.31M sold.

Point72 Asset Management first reported a position in URGN in Q3 2018 and held it in 14 quarters. The position peaked at $41.1M in Q2 2024. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Point72 Asset Management reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 168,779 UroGen Pharma shares in Q3 2025, an estimated $2.31M.
  • Point72 Asset Management first reported a position in UroGen Pharma in Q3 2018 and held it in 14 quarters.
  • Point72 Asset Management's UroGen Pharma position peaked at $41.1M in Q2 2024.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.